Global /United States /Healthcare /Drug Manufacturers - General /DERM
chevron_leftBack
Journey Medical Corp. logo

Journey Medical Corp.

DERM
NASDAQ: DERM Delayed
5.02USD -4.7%
As of 13 June 2026, Journey Medical Corp. has a market cap of $137.06M USD, ranking #23428 globally and #3702 in the United States. It ranks #2101 in the Healthcare sector, and #756 in the Drug Manufacturers - General industry.
Global Rank
23428
Country Rank
3702
Sector Rank
2101
Industry Rank
756
Key Stats
Market Cap
$137.06MUSD
Enterprise Value
$145.07MUSD
Revenue (TTM)
$61.86MUSD
EBITDA (TTM)
-$3.91MUSD
Net Income (TTM)
-$11.43MUSD
EBITDA Margin
-6.3%
Profit Margin
-18%
Forward PE
69.2
PS Ratio
2.3
PB Ratio
4.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Claude Maraoui open_in_new
Employees
58
Founded
2014
IPO
12 Nov 2021
Website
journeymedicalcorp.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-4.7% -0.8% 9.3% -40% -38% -34%

News

Loading...

DERM Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
DERM
Journey Medical Corp
ISIN: US48115J1097
Shares Out.:
21.535M1 Shares Float: 13.563M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
5.02 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Journey Medical Corp.

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
PE
LLY
$761.68B
556K%
38.1
JNJ
$547.28B
399K%
26.4
ABBV
$360.63B
263K%
97.4
MRK
$274.03B
200K%
15.1
PFE
$149.38B
109K%
19.5
$117.58B
86K%
16.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
$321.52B
256.25B CHF
234K%
19.9
AZN
$288.84B
215.59B GBP
211K%
27.6
NOVN
$274.65B
218.9B CHF
200K%
20.5
NOVO-B
$181.82B
1.18T DKK
133K%
11.5
SAN
$110.1B
95.26B EUR
80K%
19.9
GSK
$108.46B
80.96B GBP
79K%
14.6
chevron_leftBack